Iridium's $54 Deal Is Really a Rocket Lab Arbitrage — and the Spread Isn't Free Money

Iridium Communications is up about 171% this year to around $47 a share, a run that looks like the story of a stock finally getting respect. It isn't. Very little of Iridium's current price comes from its own business at all. Nearly all of it is a claim on one event: Rocket Lab's pending offer to buy the company, announced at the end of June, for $54 a share in cash and stock. Once a deal like that is in the air, the satellite-services operator stops trading on its own earnings and starts trading on the odds that the deal closes, and on the price of the acquirer's stock. That is the whole game now.

What a merger arb actually is

In plain terms, when Company A agrees to buy Company B for a fixed value, B's shares usually trade below that value until the deal closes. An arbitrageur buys B, pockets the difference at closing, and gets paid for taking the risk that the deal falls apart or takes longer than expected. Iridium is that Company B today.

The headline number is $54 a share, or roughly $8 billion in enterprise value. But only $27 of it is cash. The other $27 is paid in Rocket Lab (RKLB) stock, structured so its value is anchored to a reference price of $84.54 and protected by a collar with a floor of $67.50 and a cap of $112.50. Within that band, the number of shares flexes to keep the stock leg worth about $27. Outside it, the leg's value is whatever that fixed share count is worth.

That collar is the part most retail write-ups skip, and it is the part that matters. Rocket Lab stock has been sliding — it is down more than 20% over the last month to about $64, now below the $67.50 floor. That means holders of the Iridium portion are no longer being paid a fixed $27 of stock; they are being offered a fixed number of shares, and those shares are worth roughly $25.50 at today's price. Add the $27 cash and the full consideration comes to about $52.50 a share — not $54.

So Iridium at $47.14 is trading about $5 shy of the current deal value, a discount of roughly 10%. The market is not pricing certainty; it is pricing waiting and risk.

Why the spread exists

Three things sit inside that discount, and all three are rational. First, the deal has not closed. The antitrust review cleared when the Hart-Scott-Rodino waiting period lapsed in August, and Rocket Lab has filed its registration statement and its applications with the FCC for permission to transfer Iridium's licenses. But the FCC consent is still pending, and Iridium shareholders have not yet voted. Rocket Lab itself guides to a close in mid-2027 — roughly ten months away. Capital tied up for ten months for an event that might not happen is not a free lunch; it is a wage.

Second, the consideration is partly riding in a volatile stock. The "hold at current levels" thesis is really two bets stacked: that the deal closes, and that Rocket Lab's stock does not keep falling and drag the payout down with it. Because the stock leg now sits below the collar floor in fixed-share territory, every dollar Iridium's buyer loses is a dollar off what Iridium holders are owed at closing.

Third — and this is where a fundamentals investor has to be plain — Iridium's own numbers no longer move the price. In its most recent quarter it grew revenue 4% year over year to $225 million, but earnings were crushed to $0.09 a share by deal-related charges, and the company has suspended its conference call and guidance while the sale is pending. The GARP-style test of quality, growth and valuation that would normally decide a satellite stock is mostly moot here. You are not buying a growing business at a discount; you are buying the distance between a deal price and a market price, plus your opinion of the acquirer's stock.

The honest hold

Given the deal has cleared antitrust, the buyer is funding it with real money (a bridge facility and an equity program), and the only meaningful hurdles left are FCC sign-off and a shareholder vote, a broken deal is not the base case. So a short is not obviously attractive, and that argues for holding rather than betting against it.

The converse is also true, and it is why I would not chase it as the "buy" the 171% year implies. A ~10% spread over a ten-month horizon, in a deal whose payout is partly tied to a stock that has fallen 20% in a month, is not the kind of gap the contrarian in me gets excited about. It is compensation that roughly matches the risk. The market's discount is skepticism, not panic, and a spread like this one is closer to fair pricing than to an overdone selloff.

The single thing that changes the story is whether the deal actually completes and what Rocket Lab's stock does while you wait. If the FCC objects, shareholders vote it down, or financing stumbles, Iridium collapses back toward the value of its own modestly-growing, heavily-levered business — a number far below the deal price. If the deal closes, your payoff is not cash; it is a stake in a now highly-levered Rocket Lab, whose shares you are now outright exposed to. Either path, the profit and the risk are Rocket Lab's, not Iridium's.

That is why "hold at current levels" is the right posture for the money that is already at risk here — not because the deal is certain, but because at today's spread the risk and the reward are roughly in balance. Iridium has stopped being a satellite company you analyze and become a merger you monitor.